secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001193125-25-037650
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine: 2024 net loss $109.4M, bitopertin NDA on track H2 2025 via accelerated approval
--------------------------------------------------------------------------------

- Full-year 2024 net loss $109.4M vs $76.4M in 2023; R&D expenses rose to $96.7M.
- Cash $489.9M at year-end; plus $243.3M net from Jan 2025 offering, funds operations into 2028.
- Bitopertin: FDA path to accelerated approval for EPP; NDA submission planned H2 2025.
- DISC-0974: Phase 2 MF anemia trial initiated; initial data expected H2 2025.
- DISC-3405: Phase 2 in polycythemia vera expected H1 2025; Phase 1 showed proof-of-mechanism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312525037650/0001193125-25-037650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312525037650/d916827d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-037650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer